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Background: Exacerbations, a leading cause of hospitalization in patients with chronic obstructive pulmonary
disease (COPD), affect the quality of life and prognosis. Treatment recommendations as provided in the evidence-
based guidelines are not consistently followed, partly due to absence of simplified task-oriented approach to care.
In this study, we describe the development and implementation of a clinical pathway (CP) and evaluate its
effectiveness in the management of COPD exacerbation.
Methods: We developed a CP and evaluated its effectiveness in a non-randomized prospective study with
historical controls on patients admitted for exacerbation of COPD to Universiti Kebangsaan Malaysia Medical Centre
(UKMMC). Consecutive patients who were admitted between June 2009 and December 2010 were prospectively
recruited into the CP group. Non-CP historical controls were obtained from case records of patients admitted
between January 2008 and January 2009. Clinical outcomes were evaluated by comparing the length of stay (LOS),
complication rates, readmissions, and mortality rates.
Results: Ninety-five patients were recruited in the CP group and 98 patients were included in the non-CP historical
group. Both groups were comparable with no significant differences in age, sex and severity of COPD (p= 0.641).
For clinical outcome measures, patients in the CP group had shorter length of stay than the non-CP group (median
(IQR): 5 (4–7) days versus 7 (7–9) days, p< 0.001) and 24.1% less complications (14.7% versus 38.8%, p< 0.001). We
did not find any significant differences in readmission and mortality rates.
Conclusion: The implementation of CP –reduced the length of stay and complication rates of patients hospitalized
for acute exacerbation of COPD.
Keywords: Chronic obstructive pulmonary disease, Clinical pathway, Clinical outcomes, Length of stayBackground
Chronic obstructive pulmonary disease (COPD) is char-
acterised by progressive, partially reversible airflow
obstruction and lung hyperinflation with significant
extra-pulmonary manifestations and co-morbid condi-
tions [1]. COPD is the fifth leading cause of death world-
wide and the 12th leading cause of disability [1,2]. In
Asia, WHO estimates that the number of COPD cases
will exceed by three times the total number of COPD
cases for the rest of the world by the year 2020 [3]. In
Malaysia, COPD ranked fifth in terms of disease burden
[3] and its prevalence is projected to rise. This chronic* Correspondence: draniza@gmail.com
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reproduction in any medium, provided the orcondition is progressive in nature resulting in a steady
decline in lung function. Its progression is accelerated by
episodic exacerbations, typically requiring inpatient hos-
pital care at increasing frequency as the disease pro-
gresses. A COPD exacerbation is characterized by an
acute worsening of the patient’s baseline symptoms in-
cluding dyspnoea, cough and/or sputum, which may re-
quire alteration in regular medication.
Exacerbations, a leading cause of hospitalization in
patients with COPD, affect the quality of life and prog-
nosis. All-cause mortality after hospitalization for COPD
exacerbation is high up to 50% particularly in those re-
quiring ventilator supports [4]. Patients with frequent
COPD exacerbations have poorer quality of life and
accelerated decline in lung functions. Suboptimal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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increases health-care resources utilization and cost, and
may sometimes cause detrimental effects to patients.
Treatment recommendations as provided in the evidence-
based guidelines are not consistently followed.
A large study in USA involving 70,000 patients ad-
mitted for acute COPD exacerbation found that only
30% patients received all the recommended treatment
according to the established guidelines [5]. We have
also previously shown that the compliance to our na-
tional guideline of COPD management was only 60%
for the treatment of moderate to severe stable COPD
[6]. Among the reasons for failure to adhere to the
treatment recommendations include lack of awareness
of the COPD guidelines particularly among the non-
respiratory and primary care physicians, and absence
of simplified task-oriented approach to care. Thus,
there is a critical need to address this increasing gap
between the guidelines and clinical practices, particu-
larly in the hospitals of developing countries, by imple-
menting and evaluating clinical care practices tailored
to local settings. Clinical pathways can provide a link
between establishing clinical guidelines and practicing
them.
A clinical pathway (CP) - also known as a care path-
way or multidisciplinary action plan (MAP) – is defined
as an interventional plan for the mutual decision making
and organization of care processes for a well-defined
group of patients during a well-defined period [7]. The
pathway outlines the main clinical interventions that are
carried out in the hospital by a group of health care pro-
fessionals responsible for the care of the patient. It
incorporates locally agreed clinical standard practices as
well as guidelines into a systematic approach for man-
aging a specific group of patients with the aim of im-
proving patient outcomes, promoting patient safety,
increasing patient satisfaction, and optimizing the use of
resources [7].
COPD presents a significant disease burden in Malay-
sia and is reflected in hospital admission rates for COPD
exacerbations. The management of COPD admissions
is guided by local standard practices and clinical guide-
lines established by the Ministry of Health of Malaysia.
However there are inconsistencies between guidelines
and their application in daily clinical practice. While
existing clinical guidelines for COPD provide evidence-
based and consensus-derived statements of optimal
care for patients with COPD, such guidelines do not
provide an organizational framework for managing
patients within a hospital setting, resulting in inconsis-
tent application of clinical plans and variable patient
outcomes. COPD CP has been successfully implemented
in developed countries [8] and previous studies suggest
that its usage results in improved clinical outcomes [9,10].The adoption of COPD CP in Asia, however, lags behind
and evidence of its effectiveness in developing countries is
less clear.
To date, there has been no published study on the ef-
fectiveness or impact of COPD clinical pathway develop-
ment and implementation in Malaysia and also very few
studies worldwide. In view of the positive outcomes
reported in the literature in decreased LOS and readmis-
sion, we decided to examine the benefits and its
effectiveness.
In this study, we report the development and imple-
mentation of a COPD CP in a teaching hospital in Ma-
laysia, and evaluate its effectiveness by comparing the
length of stay (LOS), complication rates, readmissions,
and mortality between CP and non-CP COPD patients.
Methods
This was a non-randomized, prospective study with his-
torical controls in hospitalized patients with COPD in
the Universiti Kebangsaan Malaysia Medical Centre
(UKMMC). The study was carried out over a period of
31 months, from June 2008 to December 2010 starting
from the development of COPD until patient recruit-
ment. The CP was implemented in June 2009. All
patients gave written informed consent and the study
was approved by the Research and Ethics Committee of
the Faculty of Medicine, Universiti Kebangsaan Malaysia
(FF-154-2008).
The study population consisted of two groups which
were the non-clinical pathway (non-CP group) and the
clinical pathway group (CP group). The CP group was
recruited prospectively from patients that were admitted
with exacerbation of COPD between June 2009 and De-
cember 2010. For this study, an acute exacerbation of
COPD (AECOPD) was defined as an acute worsening of
dyspnoea, cough or change in quality or quantity of spu-
tum requiring a change of regular medication. These
symptoms should have been present for at least 3 days.
We included adult patients aged 40 years and above with
a diagnosis of exacerbation of COPD, and excluded
patients with the following conditions: (i) congestive car-
diac failure, (ii) long term oxygen therapy use (LTOT) ≥
15 hours/day, (iii) underlying malignancy, (iv) active tu-
berculosis, (v) diffuse interstitial lung diseases, or (vi)
pulmonary thromboembolic disease. Patients with LTOT
were excluded as co-existing cor pulmonale would be a
confounding factor that could prolong the length of
hospitalization. Patients on LTOT represent a small sub-
set of COPD patients in the advanced stages of their dis-
eases. We chose to exclude these patients in our study.
For the non-CP group, COPD patients were recruited
retrospectively from the medical records of patients ad-
mitted with a diagnosis of exacerbation of COPD be-
tween January 2008 and January 2009. Besides the
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evidence of spirometry readings consistent with COPD:
obstructive lung disease FEV1/FVC <70% with minimal
reversibility (<12%), together with a significant smoking
history of more than 10 pack-years. In our teaching hos-
pital, the GOLD [2,11] and Malaysian Clinical Practice
Guidelines (CPG) were available as references for the
management of acute COPD exacerbation [1]. We lim-
ited the retrospective review of cases to 1- year (Jan
2008 to Jan 2009) prior to commencement of the pro-
spective recruitment of the CP group (June 2009), so as
to ensure the treatment regimes and access to pulmon-
ary rehabilitation programs were comparable.
For comparison of both groups, we collected demo-
graphic data (age, gender, education, working status) as
well as baseline characteristics (BMI, smoking status,
COPD severity, and co-morbidities). Both groups were
matched for age, gender and severity of COPD. COPD
severity was classified based on the percentage predicted
FEV1 in accordance to GOLD guidelines: stage 1 > =
80%; stage 2: 50–80%; stage 3: 30–49%; and stage
4 < 30%. (Table 1) [11]. In both groups all the data were
documented and collected by medical officers who were
in charged in the medical wards.
Development and implementation of the COPD clinical
pathway
The paper-based pathway for COPD was developed by
Universiti Kebangsaan Malaysia Medical Centre
(UKMMC) in collaboration with United Nations Univer-
sity International Institute for Global Health (UNU-
IIGH). The development was conducted in series of
workshops involving the Respiratory Unit of UKMMC,
UNU-IGH, and the Department of Public Health. In the
first phase, we determined the roles of the healthcare
teams involved in the management of a COPD patient.
This included the respiratory consultant and specialist,
medical officers, the head nurse, staff nurses, pharma-
cist, dietitian, physiotherapist, and social worker. The
clinical management of COPD was based on GOLD [12]
and NICE [13] guidelines, as well as local best practices
[1], but team members were allowed to deviate from the
pathway depending on the clinical progress of the pa-
tient. We used this as a framework to decide on
optimum days in the ward, the usage of oxygen therapy,
antibiotic requirement and regimes, DVT prophylaxisTable 1 Stage of COPD and percentage predicted FEV1
Stage of COPD Percentage predicted FEV1
Stage 1 > Or = 80%
Stage 2 50–80%
Stage 3 30–49
Stage 4 <30%and others. As a baseline, the expected length of stay
was set at 5 days.
The COPD CP consisted of day-to-day assessment of
the patients starting from day 1 until the day of dis-
charge. These assessments included physiotherapy as-
sessment, oxygen requirement assessment, treatment
regimes; bronchodilator therapy corticosteroid and anti-
biotic requirement, deep venous thrombosis (DVT),
fluid regime, blood tests and chest radiograph require-
ment were also listed in the assessment chart in the CP .
In the second phase, a pilot study was carried out to
evaluate the feasibility of the COPD clinical pathway,
and to modify the pathway accordingly Prior to starting
the pilot study there was an official launch of the clinical
pathway at the hospital level. This was officiated by the
director of the UKMMC and attended by representatives
from nurses, physiotherapists, pharmacists as well as
medical doctors. A separate session to introduce the CP
to the medical department was done as a continuous
medical education (CME) session to the medical officers,
house officers, nurses, pharmacists and physiotherapists
who were based in the medical wards. The CME session
was done to explain the clinical pathway in brief and
outline the main roles to be played by each unit. In the
third phase, we implemented the COPD CP in the med-
ical wards in June 2009.
Piloting of the care pathway in subsets of patients
Patients admitted to the medical wards with a diagnosis
of exacerbation of COPD were screened within 24 hours
of admission and managed according to the COPD CP if
the patients fulfilled the inclusion/exclusion criteria. The
CP worksheets were attached to the patient’s records,
and to ensure compliance to the CP, we designated one
study investigator (medical officer) to review the clinical
pathway records daily and prompt the team to follow
the specific goals set for each day. The study investigator
performed daily ward rounds to enforce compliance on
the usage of the pathway. The health care providers were
given encouragement and reinforcement to implement
the clinical pathway. Additional educational activities
were also given to address specific issues raised during
the implementation.
Evaluation of COPD CP
The evaluation focused mainly on the care process and
outcomes. The variables that were measured for evalu-
ation were length of hospital stay (LOS), complications
or morbidity, readmission and mortality. Confounders of
LOS would include smoking status of patient, hospital
acquired infections, and worsening of co-morbidities.
In this study readmission was defined as any un-
planned hospital admission within 30 days after dis-
charge. Patients were given the status of readmission
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ily related to the initial episode of COPD exacerbation.
The interval of follow up was 30 days and this was done
via a telephone call. Complications were defined as any
disease or injury that developed during the treatment of
a pre-existing disorder. It can vary from complication
related to the pre-existing disease or non related.
Statistical analysis
Sample size determination was calculated using Power
and Sample Size Program (PS) package (version 3.0.43).
Statistical comparisons were performed using Statistical
Software Statistical Product and Services (SPSS) software
package (version 19) using appropriate statistical tests at
a significance level of 95%.
Results
Recruitment and baseline characteristics
The CP group was prospectively recruited from a total
of 212 patients that were admitted with a diagnosis of
COPD exacerbation between June 2009 and December
2010. Ninety-seven patients fulfilled the inclusion cri-
teria and all were recruited in the CP group (46%); 95
patients completed the study (98%). For the historical
non-CP control group, the medical case notes of 281
COPD patients admitted between January 2008 and
January 2009 were reviewed. Only 160 patients had
complete documentation of the case notes, and of these,
98 patients fulfilled the criteria and were included in the
control group (61%).
The basic demographic distributions between the CP
and non-CP groups were comparable and no significant
differences were noted in age, gender, ethnicity, and
working status (p > 0.05) (Table 2). We found that the
non-CP group comprised of patients with lower levels of
education compared to the CP group (p= 0.035).
Next we examined baseline characteristics of BMI,
smoking status, COPD stage, and co-morbidities
(Table 2). No differences were noted in the COPD stage
of disease and presence of co-morbidities (p > 0.05) be-
tween the two groups. However, the CP group had sig-
nificantly more underweight patients compared to the
non-CP group (20% vs 6.9%) (p= 0.029). When we
examined the smoking status, all patients had a history
of smoking in both groups, but the non-CP group had a
higher percentage of current smokers compared to CP
group (17.3% vs 5.3%) (p= 0.008).
Evaluation of clinical outcomes
Length of stay (LOS)
The overall length of stay ranged from 2 to 13 days. The
median LOS of the overall COPD population was 6 days
(means 6.59 ± 2.15 days). The median LOS in non-CP
group was 7 days (mean = 7.31 ± 2.75 days) whilst LOSin CP group was 5 days (5.83 ± 1.92 days) (p < 0.001)
(Table 3).
Complication rates
The CP group had less number of complications (38
patients, 38.8%) compared to the non-CP group (14
patients, 14.7%), and this difference was statistically sig-
nificant (p < 0.001) (Table 4).
The commonest complication was acute respiratory
failure leading to noninvasive positive pressure ventila-
tion (NIPPV) or invasive positive pressure ventilation
(IPPV) in both groups followed by hospital acquired
pneumonia (HAP). Other complications were acute cor-
onary syndrome (ACS), congestive cardiac failure (CCF)
or fluid overload, acute renal failure (ARF) thrombophle-
bitis and cellulitis upper gastrointestinal bleeding (UGIB)
urinary tract infection (UTI) and others, which include
uncontrolled hypertensive and diabetes, acute gouty
arthritis and stroke. (Table 4).
Number of readmissions
There were a total of 44 patients readmitted within
30 days of discharge. There was no difference between
in the number of readmissions between the groups: 22
(22.4%) in non-CP group and 22 (23.2%) in CP group
(p > 0.05).
Mortality rates
There were two deaths in the CP group (2.1%) and none
in the non-CP group (0%). This difference was not sig-
nificant (P= 0.24).
Discussion
In this study, we developed and implemented a clinical
pathway for the management of COPD exacerbations,
and compared the outcomes (LOS, complication rate,
readmission rate and mortality) of patients managed
with the COPD clinical pathway with patients previously
managed using the standard care guidelines.
As a baseline for comparison, we used historical con-
trols from patients that were most recently managed
using standard care guidelines one year prior to imple-
mentation of the clinical pathway. This control group
was comparable to the patients that were prospectively
recruited in the clinical pathway group: both groups had
similar access to drugs, pulmonary rehabilitation, and
smoking cessation clinic sessions; and their demographic
profiles were similar. We did not find significant differ-
ences in the age, gender, and ethnicity between the
groups.
The median BMI of the study population was 24.4
(20.9–27.2) which is classified as overweight following
the Malaysian obesity guidelines (MOH 2004). Sixty one
percent of the patients were overweight and obese, while
Table 2 Baseline characteristics and demographic data between two groups
Characteristic Total N= 193 Non-Clinical Pathway (n = 98) Clinical Pathway (n= 95) P value
Age (years ± sd*) 68.48 ± 8.84 68.78 ± 8.45 68.18 ± 9.27 0.641#
Gender [n(%)]
Male 168 (87.0) 82 (83.7) 86 (90.5) 0.156ƛ
Female 25 (13.0) 16 (16.3) 9 (9.5)
Ethnicity [n(%)]
Malay 51 (26.4) 25 (25.5) 26 (27.4) 0.353£
Chinese 110 (57.0) 61 (62.2) 49 (51.6)
Indian 29 (15.0) 11 (11.2) 18 (18.9)
Others 3 (1.6) 1 (1.1) 2 (2.1)
Level of education [n(%)]
No formal education 31 (16.1) 18 (18.4) 13 (13.7) 0.035ƛ
Primary 94 (48.7) 54 (55.1) 40 (42.1)
Secondary 68 (35.2) 26 (26.5) 42 (44.2)
Working status [n(%)]
Work(non-professional) 37 (19.2) 15 (15.5) 22 (23.2) 0.166ƛ
Not working 156 (80.8) 83 (84.7) 73 (76.8)
BMI in kg/m2 (range) 24.4 (20.9–27.2) 24.6 (21.5–27.5) 23.8 (19.1–27.0) 0.382α
BMI category (%)
Underweight (<18.5) 24 (14.4) 5 (6.9) 19 (20.0) 0.029£
Normal (18.5 – 22.9) 42 (25.1) 23 (31.9) 19 (20.0)
Overweight (23 – 27.4) 67 (40.1) 26 (36.1) 41 (43.2)
Obese (>27.4) 32 (20.4) 18 (25.0) 16 (16.8)
Smoking status [n(%)]
Current smoker 22 (11.4) 17 (17.3) 5 (5.3) 0.008ƛ
Ex-smoker 171 (88.6) 81 (82.7) 90 (94.7)
Stage of disease [n(%)]
Stage 2 7 (4.0) 4 (4.8) 3 (3.4) 0.924£
Stage 3 46 (26.6) 22 (26.2) 24 (27.0)
Stage 4 120 (69.4) 58 (69.0) 62 (69.7)
Co Morbidity [n(%)]
NO 83 (43.0) 38 (38.8) 45 (47.4) 0.228ƛ
YES 110 (57.0) 60 (61.2) 50 (52.6)
Types of Co morbidity[n(%)]
Hypertension 91 (47.2) 49 (50.0) 42 (44.2) 0.421ƛ
Diabetes Mellitus 37 (19.2) 18 (18.4) 19 (20.0) 0.773ƛ
Ischemic heart disease 52 (26.9) 28 (28.6) 24 (25.3) 0.605ƛ
Dyslipidemia 48 (24.9) 26 (26.5) 22 (23.2) 0.588ƛ
Chronic kidney disease 10 (5.2) 5 (5.1) 5 (5.3) 0.607£
* sd = standard deviation α=Mann Whitney U test, # = independent t test, ƛ=Pearson Chi-Square test, £ = Fisher’s Exact test, Significant level P< 0.05.
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Rampal et al. 2007 showed that the overall national
prevalence of obesity in Malaysia was 11.7% [14], how-
ever, we noted that they classified the cut-off point of
obesity as BMI ≥ 30 kg/m2. We classified obesity as aBMI ≥ 27.5 kg/m2 as recommended by the Malaysian
clinical guidelines in management of obesity 2004[15].
A total of 171(88.6%) subjects were ex-smokers and 22
(11.4%) were still actively smoking. There were more ac-
tive smokers (17%) in the non-CP group compared to
Table 3 Comparison of non-CP and CP group with








Average length of stay in days (LOS) 7.31 ± 2.75 5.83 ± 1.92 <0.001#
*Median LOS in days 7 (7–9) 5 (4–7) <0.001ψ
# = independent t test, *Median IQR (25th-75th), ψ=Mann Whitney U test,
Significant level P <0.05.
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ferences in LOS between the groups. It is unfortunate
that we failed to match this factor between the groups.
The CP group had their smoking history taken with the
knowledge that they were participating in a clinical trial.
There is a possibility that they may have under reported
their years of smoking. The historical controls from case
notes had smoking history taken and verified over a few
entries. This may have been more reflective of an accur-
ate number of pack years and smoking status. However
there was no significant association between smoking
history and length of stay in the two groups. The study
also found no significant association between smoking
history and complication. When we removed the 22
current smokers and reanalyzed the data, the length of
stay between the CP and non-CP group was still signifi-
cant (p < 0.001).
In terms of severity of COPD, majority of the patients









Type of complications (n)
Acute respiratory failure 9 5
Hospital Acquired Pneumonia 7 3
Acute Coronary Syndrome 5 0
Congestive Cardiac Failure/ 2 2
Fluid overload
Acute Renal Failure 3 2
Thromboplebitis/cellulitis 3 1
Upper gastrointestinal bleeding 1 0
Urinary tract infection 2 0
Others 6 2
Readmission (< 30 days)
No 76 (77.6) 73 (76.8) *0.907
Yes 22 (22.4) 22 (23.2)
*ƛ=Pearson Chi-Square test, Significant level P value <0.05.stage of disease. This is in keeping with the role of
UKMMC as a tertiary referral centre. Another possible
reason is most COPD patients approach their doctor at
a later stage of the disease.
As COPD patients are generally elderly, comorbidities
are expected to be higher. More than 50% of COPD
patients in this study had at least one comorbid disease.
The most common comorbid disease was hypertension.
A large study by Mannino et al. (2008) reported that
lung function impairment was associated with more
comorbid disease [16]. The risk of hospitalization and
mortality were increased with comorbid disease, in
which the mortality was worse in patients with impaired
lung function [16]. Prevalence of diabetes was found to
be increased in COPD where 15% of the patients with
COPD admitted to the hospital had diabetes mellitus
[16]. This result was almost similar to the prevalence of
diabetes in our COPD population (19.2%). Antonelli
et al. (1997) found that selected comorbids including
chronic renal failure and myocardial infarction or ische-
mia were able to predict mortality in patients with
advanced COPD [17].
This study confirmed our hypothesis that usage of CP
in the management of acute exacerbation of COPD
decreased the hospital length of stay (LOS). We found a
significant reduction in LOS of the CP group as com-
pared to the non-CP group. The overall median LOS of
COPD patients was 6 days and ranged between 2 to
13 days. The median LOS in non-CP group was 7 days
whilst the LOS in CP group was 5 days. A Study by Celis
et al. (2004), which utilized the COPD CP, also showed a
significant reduction of mean hospital stay of 13.21 days
in the control group and 10.24 days in the CP group
[18]. A similar study by Santamaria showed shortening
of 0.89 days (13.2%) of hospital stay in the pathway
group; however, this was not statistically significant [9].
This was a prospective unblinded study in a single unit
and the non-CP group had more co-morbidities. This
could have contributed to the LOS being not significant.
A retrospective study by Celis et al. (2004) also did dem-
onstrate a significant decrease in LOS [18], possibly due
to the retrospective nature of the study.
For other respiratory disease CPs, Bailey et al. (1998)
showed that the use of CP in asthma also caused reduc-
tion in the LOS [19]. This reduction in LOS was also
noted after implementation of pneumonia clinical path-
way [20,21].
There is insufficient data to indicate the optimal dur-
ation of hospitalization in patients with COPD exacerba-
tion. A study on necessary length of hospital stay for
COPD done by Mushlin et al. (1991) found that 6.9 days
was considered averaged LOS [22]. Our overall (both
non-CP and CP groups) mean LOS was 6.56 days.
We developed a 5-day COPD CP based on the
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from GOLD guidelines. Our CP was similar to COPD
CP from the Grey Bruce Health Network in this aspect
(approximately 5 days target). This study showed that
CP can help in reducing length of stay and indirectly re-
ducing cost of care.
The non-CP group had significantly more complica-
tions than the CP group (38 vs. 13). This is consistent
with the study by Santamaria et al. (2004) which also
showed fewer complications in the CP group [9]. Acute
respiratory failure (14 cases) was the most common
complication seen which is similar to the study by Santa-
maria et al. (2004) [9]. COPD patients are prone to de-
velop type II respiratory failure with CO2 retention
which would lead to mechanical ventilation support.
The number of readmissions was similar in both
groups. We found no significant difference in the num-
ber of unplanned readmissions between the two groups.
The main reason for readmission in this study was
shortness of breath. The CP group also had longer re-
admission interval after discharge. Our findings were
consistent with the study by Santamaria et al. [9]. The
earliest unplanned readmission was four days in the CP
group and one day in the non-CP group. There is an on-
going study by the EUROPEAN Quality of Care Pathways
Study on COPD (EQCP-COPD) looking at readmission
rates as a primary outcome.
There was no significant association in mortality be-
tween the non-CP and CP groups. Our finding was simi-
lar to Santamaria et al. study [9]. There were two deaths
in the CP group. Both patients were in stage IV COPD.
One was a 70-year old male ex-smoker who had hyper-
tension and ischaemic heart disease. The second subject
was an 81-year old male who had no comorbidities. Both
deaths were associated with COPD exacerbation.
We encountered minimal initial resistance to the
clinical pathway. However, this was not a major issue.
This lack of acceptance resulted in some deviation
from the clinical pathway. Several batches of medical
officers and house officers were rotated into the med-
ical unit during the duration of this study. Information
on the COPD clinical pathway may not be well disse-
minated. Our briefing sessions should have been more
regular to improve the compliance and adherence to
the CP. In our study it was not possible to screen ad-
mission during long weekends or public holidays. We
designated a single investigator to review and prompt
the doctors. This problem can be improved by appoint-
ing case managers in each ward. Due to the retrospect-
ive nature of case control section of this study, there
were a number of incomplete data documentation and
recording.
This study on COPD clinical pathway in Malaysia
showed a decrease in LOS and complications. We arecurrently evaluating the effectiveness of the CP using
this current data from a cost analysis point of view. This
will be published upon completion of analysis. We con-
tinue to improve our COPD clinical pathway by studying
the variances. We will use these to tailor the current CP
to reflect our resources available to us.
Conclusions
In conclusion we have developed and implemented the
first clinical pathway for inpatient management of acute
COPD exacerbation in Malaysia. Our study suggests that
the usage of CP in the management of COPD exacerba-
tion decreases the hospital length of stay and complica-
tion rates. The clinical pathway integrates the routine
assessment of a COPD patient. This can help identify
patients at risk of pseudomonal infections and stream-
line their antibiotic therapy. In our study doctors were
prompted to change antibiotics as well as steroid therapy
to the oral form from day 2 of admission. Doctors were
also prompted to switch to regular bronchodilator ther-
apy MDI from day 2 of admission. There was a clear dis-
charge plan listed in the clinical pathway. These factors
may have contributed to a shorter length of stay in
hospital.
We recommend its usage in other public hospitals in
Malaysia to improve the efficiency and quality of care in
COPD.
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